Biotech · Public company · New York, NY, US
Syndax Pharmaceuticals Inc
Ticker SNDX · SEC CIK 0001395937
Track this companyFree. Adds Syndax Pharmaceuticals Inc to your Dealase workspace and tells you when its record changes.
Clinical trials2515 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline15
- Intensive Chemotherapy RegimenPhase 3 · Acute Myeloid LeukemiasClinicalTrials.gov · fetched Nov 12, 2026
- RevumenibPhase 3 · Acute Myeloid LeukemiasClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- AxatilimabPhase 2 · Chronic Graft-versus-host-diseaseClinicalTrials.gov · fetched Nov 12, 2026
- ChemotherapyPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- cobicistatPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- entinostatPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- EntinostatPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 2 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- revumenibPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- RevumenibPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Chemotherapy RegimenPhase 1 · Acute Myeloid LeukemiasClinicalTrials.gov · fetched Nov 12, 2026
- HiDACPhase 1 · Acute Myeloid LeukemiasClinicalTrials.gov · fetched Nov 12, 2026
- RevumenibPhase 1 · Acute LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- RevumenibRelapsed/Refractory Acute LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Revumenib in Patients With MyelofibrosisPHASE1_PHASE2 · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07734077 · fetched Nov 12, 2026
- A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaPHASE1 · NOT_YET_RECRUITING · started Nov 18, 2026ClinicalTrials.gov NCT07283640 · fetched Nov 12, 2026
- Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationPHASE3 · RECRUITING · started Nov 25, 2025ClinicalTrials.gov NCT07211958 · fetched Nov 12, 2026
- Revumenib in Combination With 7+3 + Midostaurin in AMLPHASE1 · RECRUITING · started Dec 6, 2024ClinicalTrials.gov NCT06313437 · fetched Nov 12, 2026
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibPHASE1_PHASE2 · RECRUITING · started Sep 23, 2024ClinicalTrials.gov NCT06284486 · fetched Nov 12, 2026
- A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX GenesPHASE2 · RECRUITING · started Jun 4, 2024ClinicalTrials.gov NCT06229912 · fetched Nov 12, 2026
- A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasPHASE1 · ACTIVE_NOT_RECRUITING · started May 21, 2024ClinicalTrials.gov NCT06226571 · fetched Nov 12, 2026
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaPHASE1 · RECRUITING · started Apr 19, 2024ClinicalTrials.gov NCT06177067 · fetched Nov 12, 2026
- Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid TumorsPHASE1_PHASE2 · TERMINATED · started Apr 4, 2023ClinicalTrials.gov NCT05731947 · fetched Nov 12, 2026
- A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)PHASE1_PHASE2 · RECRUITING · started Oct 14, 2022ClinicalTrials.gov NCT05360160 · fetched Nov 12, 2026
- Study of Radiolabeled Revumenib in Adults With Acute LeukemiaPHASE1 · COMPLETED · started Aug 5, 2022ClinicalTrials.gov NCT05406817 · fetched Nov 12, 2026
- Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic CholangiocarcinomaPHASE2 · COMPLETED · started Aug 24, 2021ClinicalTrials.gov NCT04301778 · fetched Nov 12, 2026
- A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)PHASE2 · RECRUITING · started Mar 4, 2021ClinicalTrials.gov NCT04710576 · fetched Nov 12, 2026
- Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 23, 2020ClinicalTrials.gov NCT03978624 · fetched Nov 12, 2026
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationPHASE1_PHASE2 · RECRUITING · started Nov 5, 2019ClinicalTrials.gov NCT04065399 · fetched Nov 12, 2026
- A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHDPHASE1_PHASE2 · COMPLETED · started Nov 1, 2018ClinicalTrials.gov NCT03604692 · fetched Nov 12, 2026
- Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaPHASE2 · TERMINATED · started Jul 31, 2018ClinicalTrials.gov NCT03552380 · fetched Nov 12, 2026
- High Dose IL 2 and Entinostat in RCCPHASE2 · ACTIVE_NOT_RECRUITING · started May 24, 2018ClinicalTrials.gov NCT03501381 · fetched Nov 12, 2026
- A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaPHASE2 · COMPLETED · started Nov 6, 2017ClinicalTrials.gov NCT03250273 · fetched Nov 12, 2026
- Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell CarcinomaPHASE1_PHASE2 · TERMINATED · started Jun 29, 2017ClinicalTrials.gov NCT03024437 · fetched Nov 12, 2026
- Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 7, 2017ClinicalTrials.gov NCT03179930 · fetched Nov 12, 2026
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPHASE2_PHASE3 · RECRUITING · started Nov 1, 2016ClinicalTrials.gov NCT03013998 · fetched Nov 12, 2026
- Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead InPHASE1_PHASE2 · COMPLETED · started May 1, 2016ClinicalTrials.gov NCT02708680 · fetched Nov 12, 2026
- Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)PHASE1_PHASE2 · COMPLETED · started Aug 26, 2015ClinicalTrials.gov NCT02437136 · fetched Nov 12, 2026
- Expanded Access Program for RevumenibNO_LONGER_AVAILABLEClinicalTrials.gov NCT05918913 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 26, 2026 · fetched Nov 12, 2026